Although progress in conventional treatments is making steady and incremental gains to reduce mortality associated with heart failure (HF), there remains a need to explore potentially new therapeutic approaches. HF induced by different etiologies such as coronary artery disease, hypertension, diabetes, infection or inflammation results generally in calcium cycling dysregulation at the myocyte level. Recent advances in understanding of the molecular basis of these calcium cycling abnormalities, together with the evolution of increasingly efficient gene transfer technology, has placed HF within the reach of gene-based therapy. Furthermore, the recent successful completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium pump ushers in a new era for gene therapy for the treatment of HF.
INTRODUCTION
Chronic heart failure (HF) is a complex pathophysiological syndrome defined as a deficiency in the capacity of the heart to adequately pump blood in response to systemic demands. [1] [2] [3] A number of common disease stimuli (including arterial hypertension, ischemic cardiomyopathies, familial cardiomyopathies and valvular-induced myocardial pathologies) may induce HF, which affects up to 2% of the general population in the western world. HF constitutes one of the leading worldwide causes of morbidity and mortality. 2, 3 Despite important therapeutic advances in pharmacological and device therapies, the prognosis of patients with HF remains poor (up to 50% mortality rate within 4 years after diagnosis). 2, 3 Non-pharmacological therapies (such as heart transplantation and the use of implantable assist devices) are proposed in the late stages of the disease, and access to such therapies is restricted to a fraction of patients who need them. [4] [5] [6] [7] [8] Over the last decade, the description of cellular and molecular alterations during HF has provided rationale for directly intervening within the molecular foundation of cardiomyocyte. [9] [10] [11] [12] [13] At the cellular level, the pathological myocardium is constituted from a patchwork of cardiomyocytes including permanently lost myocytes, diseased and dysfunctional myocytes and non-diseased myocytes. Under stimulation from hormonal and physical stresses, there is however activation of a large number of pathophysiological signaling pathways that induce dysfunction of the primary non-diseased myocytes. In this context, gene therapy has appeared as an attractive alternative to target the dysfunctional myocytes and prevent them from being deteriorated and lost. 14, 15 Needless to say, many molecular targets have been described that are candidates for such approach but are still in the early stages of investigations. However, the recent report of human clinical trials targeting the sarcoplasmic reticulum (SR) Ca 2+ Àadenosine triphosphatase (SERCA2a) in chronic HF patients makes the HF gene therapy application closer. 16, 17 This overview will focus on the latest developments of HF gene therapy.
DEVELOPMENTS IN VEHICLES AND GENE DELIVERY TECHNIQUES FOR MYOCARDIAL GENE TRANSFER
It has been a great challenge to achieve efficient transduction and long-term transgene expression in the adult ventricular cardiomyocytes. Among the several techniques, single intracoronary infusion of recombinant adeno-associated viruses (AAVs) appears as the most appealing strategy when considering the actual results from preclinical HF models in large animals [18] [19] [20] [21] and from clinical trials in humans. AAVs are single-stranded DNA viruses (members of the Parvovirus family) that are naturally detected but non-pathogenic in humans. [22] [23] [24] [25] [26] The various AAV serotypes have been expanded to include 4120 genomes. 27 AAVs have been considered promising for gene therapies of cardiovascular diseases because some AAV serotypes (AAV1, 6 and 9) have high tropism for cardiomyocytes and ensure a stable long-term transgene expression through site-specific genomic integration for wild-type AAVs. Recombinant AAVs (rAAV) used for gene therapy, however display episome maintenance as they lack the inverted terminal repeats and viral proteins required for integration. Compared with other vectors such as retro/lentiviruses, the risk for insertional mutagenesis should thus be negligible. Finally, the risk of cell-mediated immune response to AAV is limited and dose-dependent. The development of immune-mediated myocarditis of infected heart appears theoretical and was not observed in the first phase I clinical trial in humans. A long-term follow-up will however be required to confirm these usual safety issues. [22] [23] [24] [25] [26] There are, however, some potential disadvantages with AAVs including the slow kinetics of expression, the limited packaging capability (o4.8 kb) and the natural presence of serotype-specific neutralizing antibodies in 20-40% of the human population. 28 Recent advances in AAV engineering have provided specific solutions to these issues. The kinetics of expression can be largely enhanced by generating double-stranded AAV DNA genomes (self-complementary DNA), which ensure peak expression in 3-4 weeks in animals, however it limits further the packaging cassette to 2.3 kb. 29 The presence of antibodies is a more challenging issue. These neutralizing antibodies have been shown to inhibit vector uptake, and patients with anti-AAV antibodies are therefore excluded from clinical AAV gene therapy trials. 30, 31 One of the solution may be the generation of chimeric rAAV as detailed in other reviews within this special edition of the journal. [22] [23] [24] [25] [26] TARGETING PROTEINS INVOLVED IN CARDIOMYOCYTE CA 2+ HANDLING IN HUMANS The handling of Ca 2+ during excitation-contraction coupling is a crucial feature of cardiomyocyte function. In brief, during each cycle, depolarization of the membrane causes an influx of Ca 2+ into the cytoplasm through the sequential opening of L-type Ca 2+ channels. 32 This local increase in calcium concentration close to the channel is sufficient to activate the release of calcium through the ryanodine receptor from the SR. The coupling of ryanodine receptor activity to L-type Ca 2+ channels gating is structurally based on their clustering in small cellular compartments. 32 Calcium then rapidly diffuses to adjacent sarcomeres, where it binds to troponin C, thus facilitating actin-myosin interaction for muscle contraction. Conversely, muscle relaxation is initiated by a fall in intracellular calcium that is predominantly driven by SERCA2a-mediated reuptake of calcium into the SR and by the sarcolemmal Na + -Ca2 + exchanger. 32 Abnormal handling of Ca +2 is a hallmark of HF. Among the calcium-handling protein defects that have been described, the loss of SERCA2a activity and the resultant decrease in SR calcium reuptake is a common feature of the failing cardiomyocytes, including in humans. It is beyond the scope of this brief review to detail the numerous experiments that have shown the positive effects of SERCA2a gene transfer in animal models of HF. 33, 34 Restoration of the calcium transient morphology in cardiomyocytes isolated from failing human hearts has also been reported after adenovirus-mediated gene transfer of SERCA2a.
SERCA2A GENE THERAPY
It was initially shown that transgenic animals overexpressing SERCA2a are associated with increased contractility without any pathological effects on the myocardium. 35, 36 It should be noted that the overexpression of SERCA2a at the protein level could only be achieved at B1.5. Homozygous null (SERCA2 À/À ) mice die early in development whereas heterozygous (SERCA2 +/À ) mice have been developed with a 65% decrease in SERCA2 protein levels, and although no cardiac pathology was found, when stressed by pressure overload, they developed HF much more quickly than wild-type control mice. 37 Furthermore, these mice showed an impaired intracellular Ca 2+ homeostasis and decreased rates of myocardial contractility. 37, 38 Thus, these studies employing transgenic and gene knockout animal models showed that SERCA pump level is a critical determinant of SR function and changes in its level can modify contractility at the cellular and organ level especially in response to stress.
Gene therapy as a method to specifically enhance SERCA2a activity was started with early reports of SERCA2a gene transfer in neonatal cardiac myocytes followed by the restoration of contractile function in cardiac myocytes isolated from patients with HF. 39, 40 This was followed by evidence of improvement in contractile function in rodents with HF. 41, 42 Finally, gene transfer of SERCA2a was found to be effective in large animal models of HF. 18 Most importantly in a preclinical model of HF, it was found that SERCA2a improved the contractile function in a dose-dependent manner. 20 These dose-gene effects were critical in validating the biological significance of enhancing SERCA2a function in the setting of HF.
Even though a number of vectors were used to deliver SERCA2a gene to the heart, recombinant adeno-associated vectors have proven to have the essential features for long-term expression.
Beyond its effects on myocardial contractility, SERCA2a overexpression has specific effects on other cardiovascular targets that in combination improve its therapeutic effects in HF. In preclinical HF models including rodents, porcine and sheep, AAV-mediated SERCA2a overexpression significantly improved cardiac metabolism (as measured by the ratio of creatine phosphate to ATP ratio), and energy utilization (as measured by restoration of the O 2 consumption to maximal systolic elastance relationship to normal levels) even when the underlying pathophysiology or insult (for example, mitral valve rupture or pacing-induced HF) was not fixed. 18, 20, 43 The restoration of myocardial energetics is an important issue because increased myocardial contractility is associated with greater energy demands. These studies showed a beneficial remodeling following SERCA2a overexpression within cardiomyocytes restoring the metabolic machinery to normal. It has also been shown that in an HF model, coronary flow increased following AAV1.SERCA2a gene transfer. We found that endothelial nitric oxide synthase (eNOS) expression and the activity of eNOS promoter were greater in SERCA2a-overexpressing human endothelial cells. We also demonstrated that in SERCA2a-overexpressing cells, Ser1177eNOS phosphorylation was increased in basal state. Furthermore, we demonstrated by co-immunoprecipitation that SERCA2a and eNOS are associated in functional protein-protein complex. This indicates that both proteins are localized in a similar calcium environment and also suggests that SERCA2a may directly control eNOS activity. Our results suggest that increased coronary flow occurring after intracoronary SERCA2a gene transfer in an HF model may be because of increased eNOS expression and activity in the coronary artery endothelial cells.
One of the early concerns with SERCA2a overexpression was that with additional SERCA2a pumps, the SR would trigger calcium release especially with leaky ryanodine receptors. 44 In addition, the inhomogeneous expression of SERCA2a can induce pro-arrhythmogenic effects in this setting. We and other investigators embarked on an extensive evaluation of whether SERCA2a overexpression can induce ventricular arrhythmias. In a rodent model of ischemia-reperfusion, we found that SERCA2a overexpression decreased the ventricular arrhythmias. 45 These results were further corroborated in a large animal model of ischemia reperfusion. 46 More recently, another group found that the overexpression of SERCA2a suppresses electrical alternans, 47 interrupting an important pathway leading to cardiac fibrillation.
Cellular remodeling: The decrease in intracellular calcium and its redistribution within the SR decreases the activation of various kinases and proteases that are involved in the hypertrophic response. 48 This improvement in calcium cycling induces transcriptional and proteomic changes as the cell remodels.
The effects of SERCA2a on contractility along with the ancillary effects have led to the overall improvement in not only overall cardiac function but also in survival in the experimental models. Furthermore, SERCA2a overexpression in these animal models led to by-stander effects so that isolated cardiomyocytes that were not infected in vivo had improved contractile function. This phenomenon was also observed in other studies with gene therapy targeting S100A1. 49 Following these promising preclinical results, approval has been gained for application in humans.
The first clinical trial of gene therapy in patients with HF was launched in the United States in 2007. 16, 50 CUPID (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) is a multicenter trial designed to evaluate the safety profile and the biological effects of gene transfer of the SERCA2a complimentary DNA by delivering a rAAV1 (AAV1.SERCA2a) in patients with advanced HF. Participants in this trial were administered a single intracoronary infusion of AAV1.SERCA2a in an open-label approach. 16, 50 Cohorts 1-4 of three patients each received sequentially a single escalating dose of AAV1.SERCA2a. A 12-month follow-up of these patients showed an acceptable safety profile. 16, 50 Improvement was detected in several patients, reflected by symptomatic (five patients), functional (four patients), biomarker (two patients) and left ventricle function/remodeling (six patients) parameters. Although this was a phase 1 study involving a small number of patients, early results found that AAV1.SERCA2a treatment conferred quantitative biological benefit. In the phase 2 trial, 39 patients with advanced HF were randomized to receive intracoronary adeno-associated virus 1 (AAV1)-mediated SERCA2a gene delivery (in one of three doses (low dose-6Â10 11 DNase-resistant particle, middle dose-3Â10 12 DNase-resistant particle and high dose-1Â10 13 DNase-resistant particle) versus placebo. Patient's symptoms (NYHA (The New York Heart Association) class, Minnesota Living With Heart Failure Questionnaire (MLWHFQ), functional status (6-min walk test (6MWT) and maximal oxygen consumption (VO2 max)), N-terminal prohormone of brain natriuretic peptide levels and echocardiographic measures were evaluated over 6 months. Treatment success was determined by examining concordant trends in the above end points for groupand patient-based comparisons, as well as clinical outcomes. The AAV1.SERCA2a high-dose group met the prespecified criteria for success at the group and individual patient levels. AAV1.SERCA2a-treated patients, versus placebo, demonstrated improvement or stabilization in NYHA class, MLWHFQ, 6MWT, VO2 max, N-terminal prohormone of brain natriuretic peptide levels and left ventricle endsystolic volumes. Significant increases in time to adjudicated cardiovascular events, and a decreased frequency of cardiovascular events per patient were observed in all patients receiving AAV1.SERCA2a. No increases in adverse events, disease-related events, laboratory abnormalities or arrhythmias were observed in AAV1.SERCA2a-treated patients compared with placebo. 51 Two other clinical trials targeting SERCA2a are currently enroling patients. The first trial is in patients with advanced HF having received left ventricular assist devices at least 1 month before treatment and who will receive either AAV1.SERCA2a or saline. This trial is being conducted in the United Kingdom. A second phase 2 monocenter double-blind randomized placebo-controlled, parallel study will be held in the Institute of Cardiology Pitié-Salpêtrière, Paris, France, with the primary objective to investigate the impact of AAV1.SERCA2a on cardiac remodeling parameters in patients with severe HF.
IN VIVO CARDIAC-TARGETED KNOCKDOWN USING AAV TECHNOLOGY
Even though gene therapy is based on recombinant protein expression as a basic principle, recent studies have established the usefulness of gene transfer vectors based on AAV for expressing regulatory RNAs. 52 Rather than a gene substitution, the concept is now to express a noncoding small RNA molecule (called short hairpin RNA (shRNA)) that will suppress the expression of an endogenous targeted gene by the mechanism of RNA interference (RNAi). In few words, mammalian cells are able of eliciting a sequence-specific posttranscriptional gene regulation. This can be achieved endogenously through the so-called microRNAs that are highly conserved small RNAs (21mer) able to bind the 3¢-untranslated regions and subsequently regulate the expression of genes. MicroRNAs are produced through a cascade of biochemical events that is mainly shared by RNAi. Indeed, such endogenous mechanism can be activated by the direct transfer of small interfering RNAs or by vectors encoding shRNA, double strand ligated with a loop sequence, processed within cells like endogenous microRNAs to form small interfering RNAs. The extent of complementarity between the guiding strand and the target mRNA will then determine whether mRNA silencing is achieved by site-specific cleavage of the message in the region of the small interfering RNA-mRNA duplex or through a microRNA-like mechanism of translational repression.
RNAi has thus the potential to be a novel therapeutic strategy in diverse areas of medicine, but RNAi has also become a valuable research tool to analyze the targeted proteins' function. The combination of RNAi in AAV vectors raises new perspectives for their use in vivo by (1) ensuring a stable long-term expression and (2) offering an opportunity to target a specific organ. The generation of AAV particles expressing shRNAs follows the same basic rules and protocols that have been previously established for conventional transgenes. The shRNA expression cassette comprising an RNA polymerase III (typically U6, H1) promotor is however significantly smaller than conventional inserts requiring a stuffer DNA to be added to guarantee the optimal vector genome encapsidation.
A recent study has showed the potential efficacy of this strategy in an HF model in vivo. 52 A novel vector was developed based on a cardiotropic AAV serotype 9 (rAAV9) that expressed an shRNA against phospholamban (PLB), (rAAV9-shPLB), a key regulator of cardiac Ca 2+ homeostasis. Unphosphorylated PLB keeps the Ca 2+ affinity of SERCA2a low, thus justifying efforts to ablate PLB expression during HF. Using rAAV9 expressing a fluorescent reporter (green fluorescent protein), the authors first showed that the transduction rate increases over time and reaches 90% at 1 month after a single tail-vein injection of the vector. At 3 months after rAAV9-shPLB administration, the authors found a reduction of PLB expression by around 75% compared with the rAAV9-shRNA control group. Over this period of 3 months, rats with a pressure-overload induced HF and treated with rAAV9-shPLB displayed a restored cardiac function, reversed cardiac dilation and hypertrophy and reduced cardiac fibrosis.
Beyond the therapeutic potential of PLB silencing, such study provides evidence for a new cardiac-targeted AAV-based gene silencing approach in vivo. This approach should appear as a valuable mean to investigate unknown gene function and may represent a complementary alternative to more classical approach such as tissuespecific inducible knockout models. When looking at the physiopathology of HF, numerous studies investigating the role of over expressed or over activated proteins may benefit from such novel approach.
CONCLUSION SR calcium cycling is crucial to the process of excitation-contraction coupling. Dysfunction of several calcium cycling proteins have been strongly associated with the pathogenesis of human HF. A large body of experimental findings to date have clearly demonstrated the concept that reversal of impaired calcium handling can prevent and/or partially reverse the progression of HF. The clinical trial of gene delivery of AAV1.SERCA2a in patients with HF, with its positive biological signals, has clearly demonstrated that SERCA2a is an important therapeutic target. New molecular-based strategies for restoring calcium cycling may provide a new therapeutic paradigm for patients with severe HF.
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